Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival

Persistent Diffusion-Restricted Lesions in Bevacizumab-Treated Malignant Gliomas Are Associated with Improved Survival Compared with Matched Controls

(2012) S. Mong et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials

(2012) Thierry Gorlia et al.   EUROPEAN JOURNAL OF CANCER

Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study

(2012) Whitney B. Pope et al.   JOURNAL OF NEURO-ONCOLOGY

Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria

(2012) J. G. Perez-Larraya et al.   NEURO-ONCOLOGY

Prediction of Glioblastoma Multiform Response to Bevacizumab Treatment Using Multi-Parametric MRI

(2012) Mohammad Najafi et al.   PLoS One

Advances in MRI Assessment of Gliomas and Response to Anti-VEGF Therapy

(2011) Whitney B. Pope et al.   Current Neurology and Neuroscience Reports

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab

(2010) M. Prados et al.   NEURO-ONCOLOGY

Glioblastoma: A Method for Predicting Response to Antiangiogenic Chemotherapy by Using MR Perfusion Imaging—Pilot Study

(2010) Rahul N. Sawlani et al.   RADIOLOGY

Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor–Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice

(2009) Walid S. Kamoun et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Diffusion Magnetic Resonance Imaging Detects Pathologically Confirmed, Nonenhancing Tumor Progression in a Patient With Recurrent Glioblastoma Receiving Bevacizumab

(2009) Elizabeth R. Gerstner et al.   JOURNAL OF CLINICAL ONCOLOGY

Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker

(2009) Rajan Jain et al.   JOURNAL OF NEURO-ONCOLOGY

Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients

(2009) Johannes Rieger et al.   JOURNAL OF NEURO-ONCOLOGY

Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab Treatment

(2009) Whitney B. Pope et al.   RADIOLOGY

Grading Astrocytic Tumors by Using Apparent Diffusion Coefficient Parameters: Superiority of a One- versus Two-Parameter Pilot Method

(2009) Ryuji Murakami et al.   RADIOLOGY

Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan

(2008) Sith Sathornsumetee et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM

(2008) Forrest W. Crawford et al.   JOURNAL OF NEURO-ONCOLOGY

Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy

(2008) Suja Saraswathy et al.   JOURNAL OF NEURO-ONCOLOGY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY